Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.

Peng-Fei Li,Chi-Hsiang Chung,Jhih-Syuan Liu,Chieh-Hua Lu,Sheng-Chiang Su,Feng-Chih Kuo,Li-Ju Ho,Kuan-Chan Chen,Yu-Te Su,Nain-Feng Chu,Chien-Hsing Lee,Chang-Hsun Hsieh,Yi-Jen Hung,Fu-Huang Lin,Wu-Chien Chien,Yao-Jen Liang

Therapeutic advances in respiratory disease（2022）

引用 0|浏览5

暂无评分

摘要

The use of DPP-4i decreased the risk and severity of asthma with a class effect among No-AE, AE, status of asthma events, but not in ET-tube intubated events. Our report suggests that DPP-4i may play a role in attenuating the impact of asthma on incidence in the future and on more severe forms of disease exacerbation in T2DM patients.

查看译文

关键词

acute exacerbation,asthma,dipeptidyl peptidase-4 inhibitors,type 2 diabetes mellitus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要